Original ArticleThe V-Go Insulin Delivery Device Used In Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control
Section snippets
INTRODUCTION
Despite an average decrease in hemoglobin A1c (A1C) in the US population with diabetes, two-thirds of patients treated with insulin (with or without combination treatment with oral drugs) do not meet the less than 7.0% American Diabetes Association target (1). Progressing the insulin regimen from oral agents in combination with a single daily injection of an intermediate-acting or long-acting insulin to 2 or more injections a day results in better glycemic control (2). However, insulin therapy
METHODS
The V-Go used in the program was that which is marketed in the United States. It is available in 20, 30, or 40 U per 24 hours preset basal rate with an additional 36 U of insulin available for bolus administration in 2 U increments on demand. The fill adapter was a prototype quite different and less user-friendly than the version that the company has marketed in the United States.
Physicians who expressed interest in the V-Go were offered a supply of V-Go for patients they thought would benefit
RESULTS
Available Data, Demographic Information, Medication Use, and Exposure
Two of 10 physicians from the prospective data collection did not participate in the retrospective data collection. Some patients were lost to follow-up and 1 patient developed dementia since the original data collection, which rendered the patient incapable of giving informed consent. Overall, 23 of the 31 originally treated patients (74%) were represented with clinical data.
Table 1 displays the demographic data for all
ACKNOWLEDGMENT
Valeritas supplied the V-Go and fill devices used and supported the data collection and statistical analysis with a grant.
REFERENCES (8)
- et al.
Is glycemic control improving in U. S. adults?
Diabetes Care
(2008) - et al.
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
Diabetes Care
(2008) - et al.
Development and validation of a new measure to evaluate psychological resistance to insulin treatment
Diabetes Care
(2007) - Roper Global Diabetes Program. GfK Heathcare's Roper US Diabetes Patient Market Study....
Cited by (25)
Clinical and economic considerations based on persistency with a novel insulin delivery device versus conventional insulin delivery in patients with type 2 diabetes: A retrospective analysis
2019, Research in Social and Administrative PharmacyV-Go Insulin Delivery Device: A New Tool for Primary Care Settings
2015, Journal for Nurse PractitionersCitation Excerpt :Of note, the V-Go was discontinued by 7 patients within 2 weeks due mainly to application site reactions such as redness, rash, tenderness, itching, local discomfort, pain on insertion, and low blood sugar. Study results included a statistically significant improvement in glycemic control as measured by A1c (−1.2 in 3 months), an improvement in fasting plasma glucose (−80 mg/dL in 3 months), a trend toward lower total daily insulin dose, no significant change in weight, and no increase in hypoglycemia.22 In summary, the V-Go device offers an FDA-approved, reliable option for people taking multiple doses of daily insulin and has been used clinically since 2009.
Insulin Tactics in Type 2 Diabetes
2015, Medical Clinics of North AmericaNew developments in insulin therapy for type 2 diabetes
2014, American Journal of MedicineCitation Excerpt :In a retrospective analysis of glycemic control in 23 patients who used the V-Go system for 12 weeks, the mean patient rating of the overall experience at 12 weeks was 9.1 (on a scale from 1 to 10, where 10 is most positive).94 Mean HbA1c decreased from baseline (from 8.8% to 7.6%; P = .005) while using the V-Go system and increased to 8.2% 12 weeks after the end of the trial.94 The “holy grail” for treatment of advanced type 2 diabetes requiring insulin treatment or type 1 diabetes is to create a closed loop system, or “artificial pancreas,” that releases insulin according to the patient's needs, as reviewed by Hovorka89 (Figure 1).
A Case Report of Continuous Subcutaneous U-500 Insulin Administration in a Patient with Insulin Resistant Lipodystrophy
2015, AACE Clinical Case ReportsCitation Excerpt :Thus, the V-Go® device appears to offer many of the benefits associated with CSII while decreasing many of the pitfalls noted with traditional insulin pump therapy. Our patient's outcome with V-Go® was consistent with the outcomes reported in a study of the V-Go® utilizing U-100 insulin (14). In addition to improved glucose control, she had a significant decrease in total daily insulin requirements.